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Abstract
Background: Interventions for T2DM have in part aimed to mimic exercise. Here, we have compared the independent and
combined effects of a PPARd agonist and endurance training mimetic (GW501516) and a myostatin antibody and resistance
training mimetic (PF-879) on metabolic and performance outcomes in obese insulin resistant mice.
Methodology/Principal Findings: Male ob/ob mice were treated for 6 weeks with vehicle, GW501516, PF-879, or GW501516
in combination with PF-879. The effects of the interventions on body composition, glucose homeostasis, glucose tolerance,
energy expenditure, exercise capacity and metabolic gene expression were compared at the end of study. GW501516
attenuated body weight and fat mass accumulation and increased the expression of genes of oxidative metabolism. In
contrast, PF-879 increased body weight by driving muscle growth and altered the expression of genes involved in insulin
signaling and glucose metabolism. Despite their differences, both interventions alone improved glucose homeostasis.
Moreover, GW501516 more effectively improved serum lipids, and PF-879 uniquely increased energy expenditure, exercise
capacity and adiponectin levels. When combined the robust effects of GW501516 and/or PF-879 on body weight, adiposity,
muscle mass, glycemia, serum lipids, energy expenditure and exercise capacity were highly conserved.
Conclusions/Significance: The data, for the first time, demonstrate postnatal inhibition of myostatin not only promotes
gains in muscle mass similar to resistance training,but improves metabolic homeostasis. In several instances, these effects
were either distinct from or complimentary to those of GW501516. The data further suggest that strategies to increase
muscle mass, and not necessarily oxidative capacity, may effectively counter insulin resistance and T2DM.
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Introduction
Exercise training positively affects body composition, energy
expenditure, glucose homeostasis and insulin requirements and
thus, remains a cornerstone in the prevention and treatment of
type 2 diabetes mellitus (T2DM). The beneficial effects of exercise
have fueled an interest in the development of pharmacologic
interventions that mimic aspects of it, hence the term, exercise
mimetics. While several studies have supported the role of
endurance training, relatively little is known with respect to
resistance training, or even less so the utility of a resistance-training
mimetic, for countering insulin resistance and T2DM.
Skeletal muscle is a dynamic system and exhibits remarkable
metabolic adaptations to exercise. Endurance exercise enhances
the activity and expression of key signaling intermediates,
transcriptional co-activators, and transcription factors that orches-
trate glucose transport and fatty acid utilization in skeletal muscle
and drive the biogenesis of mitochondria (reviewed in [1]). In turn,
modified expression of several of these molecules, including
CaMK [2], AMPK [3,4], PGC1a[5,6] and b[7], and PPARd
[8,9] directly alters metabolic outcomes in mice including
adiposity, glucose tolerance, oxidative capacity, and endurance
(or resistance to fatigue). Moreover, recent work has demonstrated
that pharmacologic activation of AMPK and PPARd increases
expression of oxidative genes in skeletal muscle and running
capacity in mice in a manner that partially mimics or enhances
endurance exercise training [10]. Collectively, these data and
other reports have supported therapeutic strategies that increase
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and T2DM.
In contrast to endurance exercise, the metabolic benefits of
modifying skeletal muscle in a resistance training manner are not
widely recognized. A limited number of clinical studies have
demonstrated increased muscle mass and improved glycemic
control in patients with T2DM following a resistance training
intervention (e.g., [11,12,13]). These effects appear to be partly
mediated through enhanced expression of insulin signaling
intermediates but not the activity of oxidative enzymes [14]. In
addition, data from transgenic models suggest that driving a
hypermuscular and more glycolytic phenotype will bestow
metabolic benefits. In particular, myostatin-null agouti lethal
yellow and myostatin-null obese leptin-deficient (ob/ob) mice
exhibit markedly increased muscle mass composed of predomi-
nantly fast glycolytic fibers, decreased fat mass accumulation, and
improved glycemic control compared to myostatin replete
littermates [15]. Similarly, induction of a skeletal muscle specific
and constitutively active Akt1 transgene in diet-induced obese
mice elicited hypertrophy of fast muscle fibers and increased the
expression of glycolytic enzymes [16]. These adaptations improved
multiple metabolic parameters including body composition,
glucose homeostasis, and energy expenditure. Thus, data from
clinical studies and transgenic mice contend increasing muscle
mass will improve whole-body metabolism, however, the utility of
a resistance training mimetic in a model of insulin resistance has
not been evaluated.
In the present study, we have compared the independent and
combined effects of the PPARd agonist and putative endurance
training mimetic, GW501516, and a myostatin neutralizing
antibody and potential resistance training mimetic, PF-879, on
the metabolic profile of obese and insulin resistant ob/ob mice. We
tested the hypotheses that 1) myostatin inhibition would
independently improve multiple aspects of metabolism and 2)
the combined effects of PPARd activation and myostatin
inhibition would confer more robust and widespread effects upon
the metabolism of the ob/ob mouse than either agent alone.
Materials and Methods
Mice and Interventions
All experimental procedures were approved by the Institutional
Animal Care and Use Committee of Pfizer Global Research &
Development (approved protocol #15646). Male ob/ob mice on
C57BL/6 background were purchased from the Jackson Labora-
tory (Bar Harbor, ME). At 5 weeks of age, 40 mice were divided
into 4 groups (n=10/group) of comparable mean body weights
and fasted glucose concentrations. The groups were then
randomly assigned one of the following 6-week interventions:
daily oral gavage of 0.5% methylcellulose and weekly i.p.
administration of saline (vehicle); daily oral gavage of the PPARd
agonist, GW501516 (10 mg/kg) (Sigma-Aldrich, St. Louis, MO);
weekly i.p. administration of a myostatin neutralizing antibody,
PF-879 (25 mg/kg); or GW501516 in combination with PF-879.
Mice were placed in standard housing conditions and provided
food (Lab Diet #5001, Lab Diet, Richmond, IN) and water ad
libitum unless otherwise noted.
Myostatin Monoclonal Antibody
A human monoclonal antibody, PF-879, was created in
XenoMice (Abgenix, Thousand Oaks, CA) by inoculation with
mature myostatin protein (R&D Systems, Minneapolis, MN) as
previously described [17,18]. In brief, hybridomas were generated
using standard techniques, tested for specificity to myostatin and
counter screened for growth and differentiation factor-11,
transforming growth factor-b1, activin A and BMP-5 binding.
For example, PF-879 inhibited myostatin-induced luciferase
activity with an IC50 of 12 nm in a human rhabdomyosarcoma
cell line (A204) transfected with the pGL3-(CAGA)12–luciferase
reporter gene. At a 100-fold higher concentration (1.3 mm), PF-
879 inhibited GDF-11-mediated activity by 30%, and was unable
to inhibit either activin A- or B-induced activity.
Body Composition and Muscle Weights
Body weight was measured weekly and lean and fat mass of
individual mice were quantified at baseline and end of study using
computed tomography (CT) (LaTheta, EchoMRI, Houston, TX).
Abdominal subcutaneous and visceral adipose tissues were
quantified by CT at the 3
rd lumbar vertebrae. Tissue weights
were measured at the end of the study following dissection.
Quadriceps muscle fiber areas were quantified as previously
described [16].
Metabolic Assessments
Non-fasted and fasted glucose concentrations were assessed
3 hours into the light cycle (9 a.m.) and following an overnight fast
(16 hr), respectively. Glucose tolerance was assessed at the end of
the study in fasted mice by measuring serum glucose concentra-
tions before and time points after an i.p. bolus of glucose (0.50 g/
kg) (Roche/Hitachi 912 System, Roche Diagnostics, Basel,
Switzerland). Serum insulin concentrations were measured using
a Meso Scale Discovery (MSD) assay (Gaithersburg, MD). Insulin
sensitivity was measured following a 4 hour fast by measuring
glucose concentrations before and timepoints after an i.p. bolus of
insulin (4.0 mU/g). The homeostatic model of insulin resistance
was calculated by multiplying the fasting insulin (ng/ml) by fasting
glucose concentration and dividing by 405.
Serum free fatty acids, high density lipoproteins (HDL) and
triglycerides were assessed following an overnight fast (Roche/
Hitachi 912 System). Triglycerides were also measured in liver and
muscle samples homogenized in 10 mM Tris (pH 7.4), 0.9% NaCl
and 0.1% Triton X-100. Liver and muscle (quadriceps) glycogen
concentrations were assessed as previously described [19]. Serum
adiponectin was assessed using a MSD assay.
Oxygen consumption (VO2) and carbon dioxide production
(VCO2) were measured for 24 hours of fed and 24 hours of fasted
conditions using a comprehensive laboratory animal monitoring
system (CLAMS) equipped with an Oxymax Open Circuit
Calorimeter (Columbus Instruments, Columbus, OH) as previ-
ously described (n=8/group) [17,20]. VO2 and VCO2 were used
to calculate the respiratory exchange ratio (RER) and VO2 and
RER were used to calculate energy expenditure (kcal/hr).
Performance Measures
Habitual physical activity of individual mice was monitored for
a 48 hour period in the CLAMS using photocells as previously
described [16,17]. Mice were acclimated to a motorized treadmill
(Columbus Instruments) for 3 consecutive days and physical
performance was characterized by measuring running time and
distance to failure using a previously described protocol modified
for ob/ob mice (initial speed of 8 m/min, increase of 2 m/min
every 3 min; 0% grade) [7,17].
Citrate Synthase Activity
The activity of citrate synthase in skeletal muscle lysates was
measured using an assay kit (Sigma-Aldrich, CS0720) and the
manufacturer’s protocol.
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A custom RT
2 Profiler PCR array (SABiosciences, Frederick,
MD) was used to determine the expression of the metabolic genes
listed in Table S1 and Table S2. Total RNA was isolated from the
adipose, liver, and quadriceps muscle of 8 mice/group using
TRIzol (Invitrogen, Carlsbad, CA) followed by the RNeasy Mini
Kit with on-column DNase treatment (Qiagen, Valencia, CA).
cDNA was prepared from total RNA (200 ng per 20 ml reaction)
with the RT
2 First Strand Kit (SABiosciences), and 50 ng of
cDNA in RT
2 qPCR Master Mix (SABiosciences) was applied to
each well of the 384-well array, according to the manufacturer’s
instructions. After running the PCR on a 7900HT Sequence
Detection System (Applied Biosystems, Foster City, CA), relative
quantitation for each gene was determined by normalizing to
4 housekeeping genes (Rps18, Actb, Gapdh, and Ppia) and comparing
to the untreated control for each tissue using the DDCt method.
Statistical Analysis
Significant differences between groups for dependent variables were
tested using either single-factor (group) analysis of variance (ANOVA)
or two-way (group and time) ANOVA. For single-factor and two-way
ANOVAs, Tukey’s multiple comparisons test was used for post hoc
analyses for between-group comparisons. To assess differences
between the treated and untreated groups, the ratio in the average
delta CT values were compared. The bootstrap [21] was used to
d e t e r m i n ec o n f i d e n c ei n t e r v a l s( v i at h eb i a s - c o r r e c t e dm e t h o d )a n d
statistical significance [21]. Analyses were conducted using GraphPad
Prism Statistical Software Version 5.0 (San Diego, CA).
Figure 1. PPARd activation and myostatin inhibition exert distinct effects on body composition. Male ob/ob mice were treated for 6
weeks with either vehicle (veh, open bars), PPARd agonist GW501516 (grey bars), myostatin antibody PF-879 (hatched bars), or GW501516 in
combination with PF-879 (black bars) (n=10 mice/group). Changes in body weight (A), fat mass (B) and lean mass (C) from study start to termination
are summarized. Abdominal visceral (D) and subcutaneous fat (E) were quantified for a single transverse slice acquired at the 3
rd lumbar vertebrae by
computed tomography. Muscle weights were determined at the end of study (F). Data are represented as mean +/2 SEM. *, # and 1 represent
p,0.05, 0.01 and 0.001, respectively. See also Figure S1.
doi:10.1371/journal.pone.0011307.g001
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PPARd activation attenuates body weight and fat mass
accumulation and myostatin inhibition stimulates muscle
growth in ob/ob mice
From study start to termination, daily administration of 10 mg/
kg GW501516 significantly suppressed body weight and fat mass
accumulation in mice compared to vehicle. In contrast, delivery of
25 mg/kg PF-879 one time per week stimulated body weight and
lean mass accretion. Co-treatment of mice with GW501516 and
PF-879 significantly attenuated gains in body weight and fat mass
relative to vehicle, as well as augmented gains in lean mass
(Figure 1A–C). There were not statistically significant differences
in measured food intake among groups; however, the mice
receiving GW501516 either alone or in combination with PF-879
tended to consume less (Figure S1).
To account for differences in fat mass, individual fat pad weights
and the cross-sectional area of adipocytes in the epididymal depot
Figure 2. PPARd activation increases mitochondrial activity and myostatin inhibition increases muscle fiber size in ob/ob mice. Male
mice were treated for 6 weeks with either vehicle (veh, open bars), PPARd agonist GW501516 (grey bars), myostatin antibody PF-879 (hatched bars),
or GW501516 in combination with PF-879 (black bars). Representative cross-sectional images, the mean fiber area and size distribution of muscle
fibers in the quadriceps muscle are presented in A, B and C, respectively (n=5/group). Fold changes in quadriceps MHC mRNA expression levels
relative to vehicle-treated mice are summarized (n=5/group)(D). Citrate synthase activity was measured in soleus and tibialis anterior muscles (E).
Data are represented as mean +/2 SEM *, # and 1 indicate p,0.05, 0.01 and 0.001, respectively.
doi:10.1371/journal.pone.0011307.g002
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Computed tomography of the abdomen, however, revealed
significantly less subcutaneous fat in ob/ob mice treated with
GW501516 either alone or in combination with PF-879 (Figure 1D
and E). In regards to lean mass, administration of PF-879 and PF-
879 plus GW501516 significantly increased the weight of
individual muscles $33% and $20%, respectively, compared to
vehicle (Figure 1F). Histological analyses of the quadriceps
demonstrated that PF-879-mediated increases in mean fiber area
and the percentage of larger fibers (Figure 2A–C). As shown in
Figure 2D the relative abundances of MHC IIx and IIb mRNA,
but not IIa, were slightly altered in the quadriceps muscle in
response to the interventions, but otherwise similar across groups.
Determination of citrate synthase activity revealed significantly
higher levels (19%) in the tibialis anterior of GW501516-treated
mice compared to vehicle (Figure 2E).
PPARd activation and myostatin inhibition alone and in
combination improve glucose homeostasis and
tolerance in ob/ob mice
Treatment with GW501516 and PF-879 alone significantly
lowered non-fasted glucose concentrations and when administered
concurrently mediated a dramatic 309 mg/dl decrease (all
Figure 3. PPARd activation and myostatin inhibition improve glucose homeostasis and tolerance in ob/ob mice. Following 6 weeks
administration of vehicle (Veh), GW501516, PF-879, or GW501516 concurrent with PF-879, non-fasted (A) and fasted (B) glucose concentrations were
measured. Blood glucose concentrations before and 2 hours after a bolus of glucose were measured following an overnight fast (C) and area under
the glucose curve was calculated (D). Changes in glucose concentrations in response to a bolus of insulin were measured following a 4 hr fast (E).
Data are represented as mean +/2 SEM (n=10/group). *, # and 1 denote p,0.05, 0.01 and 0.001, respectively.
doi:10.1371/journal.pone.0011307.g003
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significantly lowered by the administration of GW501516 and PF-
879 alone and in combination compared to vehicle (Figure 3B).
GW501516- and PF-879-treated mice exhibited lower fasting
insulin concentrations compared to vehicle; however, the differ-
ences failed to reach statistical significance (mean 6 SE; Veh=
19.4662.61, GW501516=13.9162.45, PF-879=14.7661.43,
GW501516+PF-879=18.5862.72 ng/ml; ANOVA p=0.26).
The calculated homeostatic model of insulin resistance, however,
was significantly improved in mice treated with PF-879
(Veh=8.7561.62; GW501516=4.5060.79; PF-879=4.446
0.59; GW501516+PF-879=6.4060.93; p,0.05).
All 3 interventions significantly improved glucose tolerance in the
ob/ob mice; however, GW501516 administration alone and
concurrent with PF-879 more dramatically suppressed glucose
excursion from baseline and facilitated disposal following the
glucose bolus (Figure 3C and 3D). As illustrated in Figure 3E, no
statistical differences in glucose lowering in response to an insulin
bolus were noted between the groups of ob/ob mice. Finally,
GW501516 and GW501516 plus PF-879 significantly decreased
liver glycogen concentrations, while PF-879 modestly but insignif-
icantly lowered glycogen content in skeletal muscle (Figure S2).
Myostatin Inhibition increases oxygen consumption and
basal metabolic rate in ob/ob mice
Oxygen consumption (VO2) and energy expenditure were
significantly increased during fed and fasted states in mice treated
with PF-879 and PF-879 plus GW501516 compared to vehicle.
No effect of GW501516 treatment alone was noted (Figure 4A and
C). Meanwhile, the respiratory exchange ratio (RER) was
modestly elevated during the fed state in mice treated with
GW501516 alone and concurrent with PF-879 (both p,0.05)
(Figure 4B).
PPARd activation and myostatin inhibition affect muscle
triglycerides, lipid profiles and adiponectin levels in ob/
ob mice
Compared to vehicle, 6-weeks of GW501516 and PF-879
administration, either alone or concurrently, significantly de-
creased muscle triglycerides and serum free fatty acids (FFAs) in
ob/ob mice, but had no effect on liver triglycerides (Figure 5A and
Figure S2). Moreover, GW501516 treatment significantly de-
creased triglyceride and increased HDL serum concentrations.
The effects of PF-879-treatment on triglyceride and HDL levels
were not statistically significant, but its co-administration did not
attenuate GW501516-mediated effects (Figure 5B and C). PF-879
independently increased serum adiponectin levels by 24% in the
ob/ob mice compared to vehicle. No treatment effects were
observed on plasma glucagon concentrations (Figure 5E).
Myostatin inhibition increases physical activity and
performance in ob/ob mice
To assess habitual physical activity in the ob/ob mice, horizontal
movement was monitored over a 48 hour period and was
increased by nearly 40% in mice treated with PF-879 compared to
vehicle (p,0.05) (Figure 6A). No effect of GW501516 was
observed. Moreover, running time and distance to failure in mice
administered PF-879 alone as well as in combination with
GW501516 were both increased .3.8- and .4.1-fold, respective-
ly, compared to vehicle (all p,0.05) (Figure 6B and C). Mice
receiving GW501516 also exhibited increased running time (2.5-
fold) and distance (2.7-fold) to failure relative to those receiving
vehicle; however, these differences were not statistically significant.
PPARd activation and myostatin inhibition differentially
affect metabolic gene expression in ob/ob mice
The effects of 6-weeks treatment with GW501516 and PF-879
alone and in combination on metabolic gene expression in muscle,
liver and adipose tissue are detailed in Table S1 and subsets are
illustrated in Figure 7. In skeletal muscle, GW501516 significantly
increased expression of genes regulating fatty acid transport at the
cell surface (CD36, SLC27A1) and mitochondrial membrane
Figure 4. Myostatin inhibition increases oxygen consumption
and energy expenditure in ob/ob mice. Indirect calorimetry was
performed following 6 weeks administration of vehicle (veh),
GW501516, PF-879, or GW501516 in combination with PF-879 to
quantify oxygen consumption (VO2) (A) and carbon dioxide production
to calculate the respiratory exchange ratio (B) and energy expenditure
(C) in ob/ob mice. Data are represented as mean +/2 SEM (n=8/group).
*, # and 1 represent p,0.05, 0.01 and 0.001, respectively.
doi:10.1371/journal.pone.0011307.g004
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oxidative metabolism (COX4I1) compared to vehicle. More
consistent and robust effects of GW501516 on these and related
genes were measured in the liver, while increased expression of
adiponectin and genes involved in fatty acid synthesis (DGAT2,
FASN) were noted in adipose. In skeletal muscle, PF-879 increased
the expression of genes involved in insulin signaling (IRS1) and
glucose transport (GLUT3) and decreased the expression of
PEPCK and FBP2 compared to vehicle as to favor glucose
utilization. Increased expression of adiponectin was also detected.
In liver, few changes were noted in response to PF-879, while
changes in adipose were largely similar to those observed in
skeletal muscle. In contrast to the physiological effects of
GW501516 and PF-879 being highly conserved with co-
administration, the changes in metabolic gene expression in
skeletal muscle were entirely distinct. In particular, the expression
of several factors in insulin signaling and glucose transport and
metabolism (i.e., IRS2, GLUT4, PDK4 and PEPCK) and fatty
acid transport (CD36 and FABP3) and oxidation (ACADM,
PGC1b) were significantly decreased in the combination group. In
the liver, the effects of GW501516 were highly conserved when
delivered concurrently with PF-879, and of note, FGF21 was
significantly increased. Changes observed in the expression of
genes of fatty acid and oxidative metabolism in adipose of mice
treated with GW501516 and PF-879 independently were largely
reflected in the combination group.
Discussion
In the present study, we show for the first time that postnatal
inhibition of myostatin improves the metabolic profile of obese
insulin resistant ob/ob mice. Administration of a neutralizing
antibody to myostatin, PF-879, led to hypertrophy of skeletal
muscle in a manner similar to resistance training. PF-879
improved metrics of glucose homeostasis, energy expenditure
and physical function in the absence of beneficial changes in body
Figure 5. PPARd activation and myostatin inhibition improve the lipid profile and alter adiponectin in ob/ob mice. Serum lipids were
analyzed following 6 weeks treatment with vehicle (veh), GW501516, PF-879, or GW501516 in combination with PF-879. Free fatty acids (A), high
density lipoproteins (HDL) (B) and triglycerides (C) are illustrated. Circulating adiponectin levels (D) and glucagon concentrations (E) are also
summarized. Data are represented as mean +/2 SEM (n=10/group). *, # and 1 indicate p,0.05, 0.01 and 0.001, respectively. See also Figure S2.
doi:10.1371/journal.pone.0011307.g005
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effects of PF-879 were distinct from, and in others complimentary
to, those induced by the PPARd agonist and reputed endurance
training mimetic, GW501516.
The discoveries of myostatin and the double-muscled phenotype
of myostatin-null mice [22] have generated great interest in
devising biotherapeutic approaches (e.g., myostatin peptides,
propeptides and neutralizing antibodies) to disrupt myostatin
signaling. These agents have unequivocally increased muscle mass
in murine models of health and neuromuscular disease and
validated myostatin as a key regulator of muscle maintenance in
adulthood (e.g., [23,24]) and even later life [17]. In the present
study, PF-879 markedly increased lean mass in morbidly obese
mice by driving the growth of both fast-twitch glycolytic and slow-
twitch oxidative fiber-enriched skeletal muscles (e.g., tibialis
anterior and soleus, respectively). In contrast to transgenic
knockout approaches to myostatin [15,25] and treatment of obese
mice with GW501516 (here and previous reports [8,26]), PF-879-
administration did not attenuate fat mass or body weight gain.
This finding is consistent with a previous report of a different
neutralizing antibody to myostatin [23,27]. Even so, the PF-879-
mediated increases in skeletal muscle mass translated into
physiological and functional improvements as reflected by
increases in VO2 and energy expenditure, habitual physical
activity and exercise capacity. These effects were unique to PF-879
and with the exception of habitual physical activity, largely
conserved when co-administered with GW501516. Moreover,
the salutary effects of GW501516 on body weight and fat
mass were equally robust in mice co-administered PF-879. These
data indicate that postnatal inhibition of myostatin increases
muscle mass in a manner similar to resistance training and
unique to GW501516, and leads to physiological and functional
improvements.
Despite the very distinct effects of PPARd activation and
myostatin inhibition on body weight and composition, both
GW501516 and PF-879 improved multiple metabolic parameters
in the obese, hyperinsulinemic and insulin resistant mice.
Administration of GW501516 and PF-879 alone and concurrently
significantly decreased fasted (all #126 mg/dl) and non-fasted
glucose concentrations, and the two interventions alone tended to
lower fasting insulin concentrations. The impact of PF-879 on both
glycemia and insulinemia was further highlighted in an improved
HOMA-IR. Meaningful changes in the response to exogenously
administered glucose were observed in all three treatment arms and
most notably in the two receiving GW501516. Consistent with
promoting oxidation of lipids in PPARd-expressing tissues,
GW501516 decreased circulating triglycerides and FFAs and
muscle triglycerides. PF-879 also decreased serum free fatty acids
and muscle triglycerides, and notably, increased serum concentra-
tions of adiponectin. The increase in muscle glycogen and decrease
in liver triglycerides experienced by the combination group suggest
the salutary effects of GW501516 and PF-879 on glucose transport
and fatty acid oxidation are synergistic and may further enhance
systemic metabolism. Overall, the data 1) for the first time show that
postnatal inhibition of myostatin can improve metabolic homeo-
stasis in obese insulin resistant mice; 2) confirm the previously
reported endurance training-like effects of PPARd activation on
metabolic parameters [8,26]; and 3) advance the notion that
strategies to increase skeletal muscle mass in a resistance training
manner improve multiple aspects of whole body metabolism.
The mechanism by which postnatal myostatin inhibition
improves metabolic homeostasis is particularly intriguing. Similar
to resistance training, conditional expression of a constitutively
active Akt1-transgene [16], transgenic deletion of myostatin
[15,25], and expression of a dominant negative ActRIIb receptor
in skeletal muscle [25], PF-879 robustly increased skeletal muscle
mass and improved glucose homeostasis and tolerance by
increasing the responsiveness to similar if not lower concentrations
of insulin; however, there are also several key distinctions. First,
the metabolic improvements observed in response to PF-879
occurred independent of decreases in body weight, adiposity or
hepatic lipid accumulation. In contrast, deletion or loss of function
mutations in myostatin, and conditional muscle-specific overex-
Figure 6. Myostatin inhibition increases habitual physical
activity and improves performance in ob/ob mice. After 6 weeks
of treatment with vehicle (veh), GW501516, PF-879, or GW501516 in
combination with PF-879, habitual physical activity was monitored and
summed for a 48 hour period (A) (n=8/group). At study end, the time
(B) and distance (C) mice were able to comply with a performance
protocol on a motorized treadmill was also measured (n=10/group).
Data are represented as mean +/2 SEM. * represents p,0.05.
doi:10.1371/journal.pone.0011307.g006
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obesity and hepatic lipid deposition [16,25,28]. Moreover, a
soluble ActRIIB/Fc fusion protein administered to high fat-fed
mice also increased muscle mass at 4 weeks, but did not affect
either fat mass or glucose concentrations until 10 weeks [29]. A
study of longer duration or conducted in a less severe model of
metabolic dysfunction may reveal similar effects by PF-879,
however, they do not account for the positive metabolic changes
observed here. Second, we observed increased energy expenditure
in mice treated with PF-879 (similar to Akt1 transgenic mice [16])
and no difference in RER compared to vehicle-treated mice. In
contrast, myostatin null mice exhibit reduced oxygen consumption
relative to body weight and increased carbohydrate utilization as
determined by a higher RER (consequent to the higher number
and percentage of fast-twitch glycolytic fibers [22,30]) [15,25]. We
posit that the systemic increase in skeletal muscle mass and
resultant increase in energy demand and expenditure largely
account for PF-879-mediated improvements in whole-body
metabolism. Third, compared to vehicle- and GW501516-treated
mice, mice receiving PF-879 had significantly increased serum
adiponectin concentrations. This is contrast to the reduced serum
concentrations of adiponectin in mice with either a loss of function
mutation in myostatin or mice overexpressing the inhibitory
myostatin propeptide on a standard diet [28,31], but consistent
with mice receiving a soluble ActRIIb/Fc fusion protein that also
exhibited a reduction in hepatic glucose production [29]. We
conclude the increase in adiponectin in part contributes to the
metabolic improvements observed in mice administered PF-879.
Collectively, these data indicate that PF-879-mediated metabolic
improvements in this model are largely consequent to the increase
in skeletal muscle- the primary site of insulin-mediated glucose
disposal that also accounts for a substantial percentage of energy
expenditure- and possibly increased adiponectin, but cannot be
explained by a reduction in fat mass or liver triglycerides.
To further explore the impact of GW501516 and PF-879 on the
metabolic profile of muscle, liver and adipose, we examined and
compared the expression of key mediators of glucose and fatty acid
metabolism. As indicated by the results and in agreement with
previous reports [26,32], GW501516 increased the expression of
genes of oxidative metabolism in skeletal muscle. These changes
were manifest in increased citrate synthase activity and lowered
muscle triglycerides and likely account for the improvements in
insulin responsiveness and glucose homeostasis. Intriguingly,
despite profound changes in skeletal muscle mass, the gene
expression profile was largely unaffected in response to PF-879.
This is in contrast to the overtly glycolytic skeletal muscle
phenotype and genotype induced by deletion of myostatin or
conditional overexpression of Akt1 [16,25], though the modest
changes in IRS1, GLUT3 and ADIPOQ in response to PF-879
may contribute to improved insulin sensitivity [33], and decreases
in PEPCK and FBP2 may promote glucose utilization and account
for the modest decrease in muscle glycogen content [34,35]. The
broad agreement between the 3 interventions with respect to
changes in gene expression in adipose implies that these effects
may simply be secondary to the improved metabolic profile in the
ob/ob mice. Overall, these data suggest that postnatal inhibition of
myostatin, unlike deletion of myostatin, overexpression of Akt1 or
administration of a PPARd agonist, does not remarkably alter the
expression of key metabolic genes in muscle, liver or adipose tissue
as a means to improve systemic metabolism.
The potential benefit of myostatin blockade for T2DM has been
substantiated by several recent studies. First, increased myostatin
expression and more impressively secretion has been observed in
muscle and adipose tissue samples derived from obese and
extremely obese women, and increased circulating levels of
myostatin in this cohort were found to be correlated with insulin
resistance [36]. Second, myostatin expression in skeletal muscle
was significantly decreased in response to weight loss in obese
patients undergoing gastric bypass surgery and associated with
increased insulin action [37,38]. Third, increased expression of
myostatin was recently detected in skeletal muscle biopsies of
healthy but at risk first degree relatives of patients with T2DM in
concert with genes of the insulin signaling pathway [39]. Coupled
with the findings of the present study, these data suggest that
myostatin likely contributes to alterations in skeletal muscle
quantity, quality and metabolism in conditions of obesity and
T2DM and a pharmacological strategy to disrupt myostatin
signaling may potentially prevent, attenuate or reverse their
progression.
In summary, the data provide convincing evidence that a
neutralizing antibody to myostatin not only promotes gains in
muscle mass similar to resistance training, but improves fasting
and fed glucose concentrations, glucose tolerance and lipid profiles
in obese insulin resistant ob/ob mice. In addition, PF-879 increased
energy expenditure and measures of physical function and did not
diminish the unique effects of GW501516 on body weight,
adiposity or serum triglycerides. These data further suggest clinical
and pharmacological strategies to increase muscle mass, and not
necessarily oxidative capacity, may effectively counter insulin
resistance and T2DM.
Supporting Information
Figure S1 Effects of PPARd activation and myostatin inhibition
on food intake and body weight in ob/ob mice. Food intake (A) and
body weight (B) were monitored weekly for individual mice for 6
weeks while treated with either vehicle (Veh), GW501516, PF-879
or GW501516 plus PF-879. n=10/group and *, # and 1
represent p,0.05, 0.01 and 0.001, respectively.
Found at: doi:10.1371/journal.pone.0011307.s001 (0.53 MB
TIF)
Figure S2 Effects of PPARd activation and myostatin inhibition
on skeletal muscle and liver glycogen and triglyceride content in
ob/ob mice. Male ob/ob mice were treated for 6 weeks with vehicle
(Veh), GW501516, PF-879 or GW501516 plus PF-879. At study
termination, the concentrations of glycogen and triglycerides were
measured in skeletal muscle (A and B) and liver (C and D) (n=8-
10/group). *, # and 1 represent p,0.05, 0.01 and 0.001,
respectively.
Found at: doi:10.1371/journal.pone.0011307.s002 (0.58 MB TIF)
Table S1 Fold changes (mean (standard error))
A in metabolic
gene expression in the muscle, liver and adipose of ob/ob mice
treated for 6 weeks with either a PPARd agonist (GW501516), a
Figure 7. The effects of PPARd activation and myostatin inhibition on metabolic gene expression in ob/ob mice. Following 6 weeks of
treatment with either vehicle (Veh), GW501516, PF-879 or GW501516 plus PF-879, mRNA was isolated from skeletal muscle, liver and adipose tissue
(A, B and C, respectively) of ob/ob mice and quantified by a low-density array card. Fold changes compared to vehicle were calculated. Data are
represented as mean +/2 SEM (n=8/group). *, # and 1 represent differences in expression of .20% relative to control and p,0.05, 0.01 and 0.001,
respectively. See also Table S1.
doi:10.1371/journal.pone.0011307.g007
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relative to a vehicle control.
Found at: doi:10.1371/journal.pone.0011307.s003 (0.13 MB
DOC)
Table S2 Symbols, aliases, and official names of genes examined
by PCR array.
Found at: doi:10.1371/journal.pone.0011307.s004 (0.08 MB
DOC)
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